Saturday, October 31, 2026

Aphria Stock Over 6% Down As Session Comes To An End On Monday

ViaNews Editorial Team

December 21, 2020

Aphria Stock Over 6% Down As Session Comes To An End On Monday

Shares of Aphria fell 6.41% to $7.16 at 15:38 EST on Monday, following yesterday's upward trend. The Nasdaq Stock Market is dropping 0.28% to $12,720.50, following yesterday's downward trend, This seems, as yet, a somewhat rough trend exchanging session today.

Aphria's last close was $7.65, 24.02% under its 52-week high of $8.88.

Aphria's Stock Yearly Top and Bottom Value

Aphria's stock is valued at $7.16 at 15:38 EST, way below its 52-week high of $8.88 and way above its 52-week low of $1.95.

Aphria's Moving Average

Aphria's worth is higher than its 50-day moving average of $6.87 and way higher than its 200-day moving average of $5.23.

Previous days news about Aphria

Aphria, tilray deal is a bet on euro pot: cannabis weekly. According to Bloomberg Quint on Sun Dec 20, "The region is particularly attractive for the hundreds of small Canadian players, who are struggling with an oversupply of raw flower and an uncertain path into the U.S. And the Aphria-Tilray deal could be the first of more Euro-centric transactions.", "Tilray has a cultivation facility in Portugal, while Aphria has another in Germany -- plus a prescription business that's connected to 13,000 German pharmacies and others throughout Europe. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com